Stellate ganglion block rectifies excessive daytime sleepiness: a case report

Jian Xu1, Qingyan Liu1, Tao Huang2, Ruiqiong Zhong1 and Yuenong Zhang1

Abstract
Excessive daytime sleepiness (EDS) is classified as a neurofunctional disorder that manifests as uncontrolled sleeping propensity in the daytime. Currently, consistent and effective therapeutic approaches for EDS are lacking. Stellate ganglion block (SGB) has a clear effect in various complicated pain syndromes, vascular insufficiency, hyperhidrosis, and posttraumatic stress syndrome. We report an EDS case that involved a patient who recovered after several sessions of SGB.

Keywords
Stellate ganglion block, excessive daytime sleepiness, physiological rhythm, sleep disorder, treatment, autonomic nerve function

Date received: 29 April 2022; accepted: 18 July 2022

Introduction
Sleep and wakefulness are among the most critical physiological rhythms in humans. A regular and healthy sleep cycle substantially refreshes the entire body, ensuring productive fitness. Conversely, abnormal sleep induces discomfort, and leads to detrimental outcomes in multiple diseases.1 Sleep disorders interrupt normal sleep patterns, which might trigger excessive daytime sleepiness (EDS). In some severe cases, patients can be woken only by very strong stimuli, which reduces their quality of life

1Department of Surgery and Anesthesia, The Third Affiliated Hospital of Sun Yat-sen University Yuedong Hospital, Meizhou City, China
2Department of Anesthesiology, Fengshun County Hospital of Traditional Chinese Medicine, Meizhou City, China

Corresponding author:
Yuenong Zhang, Department of Surgery and Anesthesia, The Third Affiliated Hospital of Sun Yat-sen University Yuedong Hospital, 124 Park North Road, New County, Meixian District, Meizhou City, Guangdong 514700, China.
Email: 36856665@qq.com
and threatens daily safety.\textsuperscript{2} Treatments for EDS comprise medication-based and non-medication approaches. Regarding the former, neurostimulants and dopamine receptor agonists are common choices, while the latter aim to recover healthy sleep routines through psychobehavioral therapies.\textsuperscript{3,4} The stellate ganglion refers to the assembly of the inferior cervical and superior thoracic ganglia, which when blocked by a local anesthetic, can resolve several complex pain syndromes, posttraumatic stress syndrome, and chronic regional pain syndrome.\textsuperscript{5} Studies have revealed that repeat stellate ganglion blocks (SGB) effectively activate autonomic nerves, thereby adjusting autonomic nerve function.\textsuperscript{6,7} By maintaining the sympathetic and parasympathetic balance, SGB is effective for migraine, cluster headache, insomnia, and premenstrual syndrome.\textsuperscript{4,5} An imbalance between sympathetic and parasympathetic tone facilitates the disruption of the sleep–wake cycle.\textsuperscript{8} Therefore, SGB might be helpful for EDS treatment. This hypothesis was confirmed in the present case, where a patient with EDS recovered dramatically after several sessions of SGB.

**Case presentation**

The present study fully conformed to the CAse REporting (CARE) guidelines.\textsuperscript{9} A female patient in her early 30s (height: 158 cm, weight: 44 kg) visited our clinic with complaints of 1 year of daytime sleepiness, weakness in the lower limbs, fecal incontinence, and urgent or frequent urination. The patient’s sleep duration was more than 8 hours each night. However, she remained somnolent in the daytime, especially when alone, and even when speaking or eating. The resulting weariness reduced her ability to perform light physical activities, and she found it difficult to stay awake and alert. She went to sleep unintentionally or at the wrong time almost every day. She also mentioned a 3-month burning sensation in both lower extremities and a 1-week-duration of poor appetite. Except for the consistent oral administration of oryzanol (30 mg/day), no other medications were recorded. The patient’s condition had been deteriorating since the onset of the symptoms, with an Epworth Sleepiness Scale (ESS) score of 19. Physical examination revealed no abnormalities. On the basis of these findings, the patient was diagnosed with EDS accompanied by autonomic nervous dysfunction. After the patient agreed to receive treatment by providing informed consent, SGB was performed in the hospital. Specifically, the patient was placed in the supine position with her head deviated to one side, without the need for local anesthetic.

High-frequency ultrasonography was performed at the C6–C7 level, with the aim of detecting the longus colli muscle. Guided by the ultrasonographic images (Figure 1), 0.16% ropivacaine (5 mL) was infused below the prevertebral fascia and above the longus colli. SGB was performed once a day for 5 minutes, alternating between the left and right sides. Horner’s syndrome appeared after each injection, indicating the efficiency of the block. The patient remained in the hospital for a 30-minute observation period after each treatment; no hospitalization was required. She received eight sessions of SGB in total, during which oryzanol was continuously administered. After the first SGB, the weakness in both lower limbs resolved. The second SGB normalized the control of voiding and defecation, the third SGB markedly relieved the EDS, and the fifth SGB mitigated the burning sensation in the lower extremities and restored the patient’s normal eating behavior. The subsequent three sessions of SGB reduced the ESS score from 19 to 0. Throughout the treatment process, the patient reported no discomfort. Furthermore, no SGB-related complications occurred, such as infection.
and bleeding, and there was no damage to the nervous system. After the final SGB, oryzanol administration was stopped. During the 3-month follow-up, no relapse of daytime sleepiness, weakness in the lower limbs, fecal incontinence, or urgent or frequent urination was reported.

**Discussion**

EDS leads to various adverse consequences, namely mind distraction, low working efficiency, and poor quality of life. The main causes are central nervous system (CNS) disorders, obstructive sleep apnea syndrome, metabolic diseases, and depression. Irregular sleepiness patterns; sleep fragmentation; abnormal concentrations of γ-aminobutyric acid (GABA), growth hormone-releasing hormone (GHRH), and melatonin (MT); and hypothalamic dysfunction may serve as underlying mechanisms. In the present case, the patient reported no history of CNS-, respiratory-, metabolism-, or psychology-related abnormalities. The severity of the patient’s daytime sleepiness, graded by the ESS score, was evaluated independently by professional assessors or in sleep labs.

The reported sensitivity and specificity of ESS is as high as 93.5% and 100.0%, respectively, making this scoring method the currently accepted choice of patients and their families, clinically. The initial ESS score of the present patient was 19, indicating a serious condition, and with her specific symptoms, the ESS score supported the diagnosis of EDS with autonomic nervous dysfunction. This condition might be correlated with abnormal function in the hypothalamus. SGB has been used to adjust the activity of the hypothalamus by refining the local circulation. This effect normalizes the homeostasis of the internal environment, stabilizes autonomic, endocrine, and immune functions, and facilitates the secretion of GHRH and MT. As a result, SGB represents a potential treatment for sleep disorders. In the present case, SGB resulted in a clear and desirable effect on the patient’s EDS and a decrease in the ESS score from 19 to 0. Additionally, the patient terminated the oryzanol when the somnolence and extreme fatigue were relieved after the final treatment. The 3-month follow-up revealed no relapse of any of the previous symptoms, namely daytime sleepiness, weakness in the lower limbs, fecal incontinence, or urgent or frequent urination, indicating that the SGB treatments recovered the patient’s autonomic activity and resolved the endocrine disorder. This result is similar to the results reported in other studies, suggesting the efficacy of SGB in stabilizing the autonomic system through reversing the autonomic imbalance.

**Conclusion**

There are currently few therapeutic approaches for EDS, and these have had
undesirable outcomes. In the present case, SGB resulted in attractive effects regarding EDS recovery, providing a novel solution for severe functional complications related to EDS. In the future, clinical multicenter studies with a large sample size are warranted to further elucidate the therapeutic value of SGB in EDS and the mechanisms underlying its effects.

Author contributions
Study design: Yuenong Zhang.
Literature search: Tao Huang and Ruiqiong Zhong.
Writing of the original draft: Jian Xu.
Writing of the literature review and editing: Yuenong Zhang and Qingyan Liu.

Availability of data and materials
All the data supporting the findings in the study are included in the published manuscript.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

Ethics statement
This study was approved by the Ethics Committee and Institutional Review Board of The Third Affiliated Hospital of Sun Yat-sen University-Yuedong Hospital (2021–11). Written informed consent was obtained from the patient for the publication of this case report and the accompanying images.

ORCID iD
Yuenong Zhang https://orcid.org/0000-0002-2318-3204

References
1. Ferini-Strambi L, Galbiati A and Combi R. Sleep disorder-related headaches. Neurol Sci 2019; 40: 107–113.
2. Meyer C, Barbosa DG, Junior GJF, et al. Proposal of cutoff points for pediatric daytime sleepiness scale to identify excessive daytime sleepiness. Chronobiol Int 2017; 16: 1–9.
3. Zarcone V, Kryger MH, Roth T, et al. Principles and practice of sleep medicine. 3rd ed. Philadelphia: Saunders, 2000.
4. Rodrigues TM, Castro CA and Ferreira JJ. Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson’s disease: systematic review and meta-analysis. Parkinsonism Relat Disord 2016; 27: 25–34.
5. Piraccini E, Munakomi S and Chang KV. Stellate ganglion blocks. 2021 Feb 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 29939575.
6. Kobayashi H, Hayashi M, Kobayashi S, et al. Effect of endothelin on the canine basilar artery. Neurosurgery 1990; 27: 357–361.
7. Palmer RMJ, Ferrige AG and Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524–526.
8. Muto V, Jaspar M, Meyer C, et al. Local modulation of human brain responses by circadian rhythmicity and sleep debt. Science 2016; 353: 687–690.
9. Gagnier JJ, Kienle G, Altman DG, et al; CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. Headache 2013; 53: 1541–1547.
10. Alemanakis R, Chung BY, Feldmann RE Jr, et al. Effectiveness, safety, and predictive potential in ultrasound-guided stellate ganglion blockades for the treatment of sympathetically maintained pain. Pain Pract 2020; 20: 626–638.
11. Ito E and Inoue Y. [The International Classification of Sleep Disorders, third edition. American Academy of Sleep Medicine. Includes bibliographies and index]. In Japanese. Nihon Rinsbo 2015; 73: 916–923.
12. Lima CA, Soares WJ, Bilton, et al. Correlates of excessive daytime sleepiness in community-dwelling older adults: an exploratory study. Rev Bras Epidemiol 2015; 18: 607–617.
13. Sharma SK, Katoch VM, Mohan A, et al. Consensus & evidence-based INOSA Guidelines 2014 (first edition). Indian J Med Res 2014; 140: 451–468.
14. Lockley SW, Skene DJ, Tabandeh H, et al. Relationship between napping and melatonin in the blind. J Biol Rhythms 1997; 12: 16–25.
15. Auld F, Maschauer EL, Morrison I, et al. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev 2017; 34: 10–22.
16. Larsen JP and Tandberg E. Sleep disorders in patients with Parkinson’s disease: epidemiology and management. CNS Drugs 2001; 15: 267–275.
17. Ruoff C and Rye D. The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: clinical relevance and practicality. Curr Med Res Opin 2016; 32: 1611–1622.
18. Xu Y and Zhang Y. Treatment of multiple physiological and psychological disorders in one patient with stellate ganglion block: a case report. J Int Med Res 2021; 49: 1–5.
19. Wang W, Shi W, Qian H, et al. Stellate ganglion block attenuates chronic stress induced depression in rats. PLoS One 2017; 12: e0183995.
20. Rae Olmsted KL, Bartoszek M, Mulvaney S, et al. Effect of stellate ganglion block treatment on posttraumatic stress disorder symptoms: a randomized clinical trial. JAMA Psychiatry 2020; 77: 130–138.
21. Schürmann M, Gradl G, Wizgal I, et al. Clinical and physiologic evaluation of stellate ganglion blockade for complex regional pain syndrome type I. Clin J Pain 2001; 17: 94–100.